The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies.
 
Gulam Abbas Manji
Honoraria - Celgene; Cend Therapeutics; Exelixis; Roche/Genentech
Consulting or Advisory Role - Cend Therapeutics; Exelixis; Ipsen; Roche/Genentech
Research Funding - Arcus Biosciences (Inst); BiolineRx (Inst); Merck (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene; Exelixis; Roche/Genentech
 
Brian William Labadie
No Relationships to Disclose
 
Shing M Lee
Consulting or Advisory Role - PTC Therapeutics
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); Karyopharm Therapeutics (Inst); Merck (Inst)
 
Ilenia Pellicciotta
No Relationships to Disclose
 
Liner Ge
No Relationships to Disclose
 
Sarah Sta Ana
No Relationships to Disclose
 
Naomi Sender
No Relationships to Disclose
 
Isabelle Ross
No Relationships to Disclose
 
Winston Wong
No Relationships to Disclose
 
Alexander G Raufi
No Relationships to Disclose